Previous 10 | Next 10 |
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Prurigo Nodularis PR Newswire Approval based on direct-to-Phase 3 program showing more than three times as many Dupixent patients (60% and 58%) experienced clinical...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...
Odronextamab (CD20xCD3) Demonstrates High and Durable Complete Response Rate among Patients with Relapsed/Refractory Follicular Lymphoma in Pivotal Phase 2 Trial PR Newswire First Phase 2 data presented at ASH showed an 82% response rate in patients with grades 1 to 3a disease...
Linvoseltamab (BCMAxCD3) Initial Pivotal Phase 2 Data Show Clinically Meaningful Responses in Patients with Heavily Pre-treated Multiple Myeloma PR Newswire As presented at ASH, recommended 200 mg dose of linvoseltamab demonstrated a 64% response rate, with 45% of responders a...
Regeneron Named on Dow Jones Sustainability World Index for Fourth Consecutive Year PR Newswire DJSI World recognizes the top 10 percent of most sustainable companies by industry; Regeneron ranked among top three biotechnology companies 1 TARRYTOWN, N.Y. , ...
Pivotal Odronextamab (CD20xCD3) Phase 2 Data in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma Debut at ASH PR Newswire 49% objective response rate ( ORR ) in heavily pre-treated patients who were naïve to prior CAR-T, with 31% achieving a complete re...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips If there’s a silver lining regarding the coronavirus pandemic, it’s that it demonstrated the importance of the top biotech stock picks for 2023. While medical innovations may seem frustratingly slow, the Covid-19 ...
Last month, Sanofi (NASDAQ: SNY) and Regeneron 's (NASDAQ: REGN) immunology mega-blockbuster, known as Dupixent, received some good news. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion, recommending approval of the d...
Equities have been southbound for most of the year. And after a solid performance in the early days of the pandemic, the biotech industry is lagging the struggling overall stock market. But some biotechs are doing great. The list includes Regeneron Pharmaceuticals (NASDAQ: REGN) and ...
If you didn’t know, biotech stocks have been on the rise in recent years, as investors seek out companies that are developing groundbreaking new treatments for a wide range of diseases. Biotech firms are often at the forefront of medical research, and their products have the potential ...
News, Short Squeeze, Breakout and More Instantly...
Regeneron Pharmaceuticals Inc. Company Name:
REGN Stock Symbol:
NASDAQ Market:
Regeneron Pharmaceuticals Inc. Website:
A look at the top 10 most actives in the United States Qualigen Therapeutics Inc. (QLGN) rose 111.4% to $0.4341 on volume of 412,713,755 shares Maxeon Solar Technologies Ltd. (MAXN) fell 1.3% to $0.2375 on volume of 280,800,277 shares NVIDIA Corporation (NVDA) rose 1.4% to $129.24 on volu...
2024-07-12 11:00:05 ET Trung Huynh from UBS issued a price target of $1,250.00 for REGN on 2024-07-12 10:18:00. The adjusted price target was set to $1,250.00. At the time of the announcement, REGN was trading at $1092.3075. The overall price target consensus is at $902....
A look at the top 10 most actives in the United States Maxeon Solar Technologies Ltd. (MAXN) rose 3.6% to $0.2493 on volume of 118,503,418 shares Qualigen Therapeutics Inc. (QLGN) rose 94.8% to $0.4 on volume of 100,863,101 shares AgriFORCE Growing Systems Ltd. (AGRI) rose 20.0% to $0.098...